First drug for postpartum depression now available in U.S., drugmaker says

Let’s look at some of the barriers to accessing these services for women with postpartum depression. The obstacles are many. So I don’t think I can even convey all of this information to you fairly. I think the first one is lack of awareness. So people just don’t realize that’s the problem they’re trying to solve. At UH Tucson, there is an approximately three-month wait to get into psychiatry. ***Many psychiatrists do not have insurance, and there are*** many cash-pay practices. So this also becomes a *** challenge. Who do you go to who can provide care? Are they certified or proficient in reproductive psychiatry management? Frankly, most mental health care providers during this time are frontline providers. So it’s obesity, it’s uh PC PS, pediatricians even take care of mom during this period. So I figured who would follow up with me to make sure I continue to stay healthy. So, are there all these places you might be missing out on? How restrictive do you think abortion is, and subsequently providers leaving certain states, interacts with access to mental health care throughout pregnancy. As fewer new graduates apply to states with more restrictive abortion restrictions. So they don’t want to practice in that state, or they don’t want to, they want to keep learning. So I think that’s the biggest challenge, that psychiatric care can be delivered electronically. So I think having state-level, federal-level policies that allow care to be provided across the United States and across the country will make it easier for people to access care. Do you think there is a need for more of this type of specialized training across the country? Oh, absolutely. For example, store your base uh cortisol level. When you end your pregnancy, you’re in a hypercortisolism state, which is your normal space, but it’s almost to the level of Cushing’s disease that’s normal during pregnancy. You must remember this. If you were to manage someone’s symptoms and administer their medications during pregnancy, your heart would move up and to the left, your lungs would be squashed, and you wouldn’t have as much room to breathe. For someone with an anxiety disorder, this could be a physical cue, right? Like my inability to take a deep breath, to them that could be a sign of anxiety that could turn into a panic attack. Finally, doctors, there is*** a new drug for postpartum depression that was approved by the FDA in August. Is this the most useful new tool? To be honest, I’m super excited about the fact that this is a completely new mechanism of action and I’m, uh, looking forward to finding out how much it’s going to cost, because we just don’t know yet. Just a 60-day intravenous treatment of its sister drug, Breen, costs up to $35,000. So I really, really hope it’s not like that, not like that dollar mark. It’s actually available for people to use. I think the other thing that I’m really excited about about this drug is that it’s short-term, it’s a ***14-day drug. So I think from a ***stigma perspective, short-term psychotropic medications, antidepressants, may actually help us build more trust in mental health supplements and taking ***short-term medications. Really, I think just having more of a community approach to dealing with this disease would help. So if you’re watching, turn on your phone, send a *** text message to a *** friend, and check in on them because it can go on for quite some time. It can last for quite some time. Thank you very much, doctor. Thanks.

First drug for postpartum depression now available in U.S., drugmaker says

The first oral drug approved in the United States to treat postpartum depression is now available by prescription, according to the drugmaker. The U.S. Food and Drug Administration approved the treatment, Zurzuvae, in August. The product is now available in specialty pharmacies and can be shipped directly to patients, Biogen and Sage Therapeutics Inc. said in a statement Thursday. However, the drug’s pre-insurance price of $15,900 per course of treatment has raised concerns among some about how many people will receive it. Zurzuvae, taken as two 25 mg capsules daily for 14 days, is used to treat adults suffering from postpartum depression, or postpartum depression, a serious mental illness that affects about one in seven new mothers after childbirth You may develop this disease later. The drugmaker noted that people taking Zurzuvae in clinical trials experienced greater reductions in depressive symptoms than patients taking a placebo, with the reductions visible within three days and in a Phase 3 clinical study. , this relief lasted for at least 45 days. Dr. Kristina Deligiannidis, a professor at the Feinstein Institute for Medical Research in New York, said: “It can take effect on the 15th day and improve symptoms within three days, which may have a profound impact on the lives of women with PPD.” The company stated in the announcement was the principal investigator on the national multicenter clinical trial that led to the approval of Zurzuvae. “This milestone will hopefully serve as a catalyst for more systemic changes for women suffering from postpartum depression, including much-needed increases in screening, diagnosis and treatment across physician specialties.” Postpartum depression symptoms can be debilitating and may include crying, and Your baby has trouble making connections, can’t sleep, or feels hopeless. Women with severe postpartum depression are unable to carry out normal daily activities and often have recurring thoughts of suicide, self-harm, or harming their baby. These are very serious symptoms that require immediate evaluation and attention. “We are committed to working with health care providers so women suffering from postpartum depression do not face this isolating condition alone,” Alisha A. Alaimo, president of Biogen’s North America organization, said in a statement. “We are proud to offer the first oral therapy specifically for women with postpartum depression, and we hope this milestone will advance ongoing efforts by federal and health organizations to improve maternal mental health care.” Biogen and Sage said Thursday it has launched a patient support program called “Zurzuvae For You,” which includes financial assistance such as a copay assistance program and free medication for those who qualify. “Innovation will have an impact only if people have access to it, and we will continue to support the goal of our support programs to, where possible, help women with postpartum depression who are prescribed Zurzuvae with virtually no out-of-pocket costs and for those without insurance Products are available at no cost to eligible patients due to perceived lack of insurance. Chris Benecchi, chief commercial officer at Sage Therapeutics, said in Thursday’s announcement that insurance or financial means should not be a barrier to accessing treatment. Other options for oral treatments for postpartum depression are Selective serotonin reuptake inhibitors, or SSRIs, are antidepressant drugs that “take weeks.” Dr. Katrina Furey, a private practice psychiatrist who specializes in women’s mental health and reproductive psychiatry and a clinical instructor at Yale University, said: Nov. Furey said Zurzuvae’s price seemed particularly high compared with those drugs. SSRIs, which include generic versions of Prozac and Zoloft, typically cost less than $20 a month, according to GoodRx. “It remains to be seen how much insurance companies will cover, or whether they will require women to ‘fail.’ “Treat with cheaper SSRIs before paying for this new therapy,” Furey said. “I hope that’s not the case and that its price won’t be a barrier to accessing this treatment.” Still, she noted, the $15,900 price tag is less than half the price of Sage’s earlier postpartum depression drug, Zulresso. The drug, which costs about $35,000, is infused intravenously in a hospital for 60 hours.

The first oral drug approved in the United States to treat postpartum depression is now available by prescription, according to the drugmaker.

The U.S. Food and Drug Administration approved the treatment, Zurzuvae, in August. Biogen and Sage Therapeutics Inc. said in statements Thursday that the product is now available in specialty pharmacies and can be shipped directly to patients.

However, the drug costs $15,900 per course before insurance, raising concerns among some about how many people will be able to access it.

Zurzuvae, taken as two 25 mg capsules daily for 14 days, is used to treat adults suffering from postpartum depression, or postpartum depression, a serious mental illness that about one in seven new mothers may experience after giving birth. will suffer from this disease.

The pharmaceutical company pointed out that people who took Zurzuvae in clinical trials experienced greater reductions in depressive symptoms than those who took placebo, and this reduction was visible within three days. In a Phase 3 clinical study, This relief lasted for at least 45 days.

“Options like Zurzuvae, which works as early as day 15 and improves symptoms as early as three days, have the potential to have a profound impact on the lives of women with PPD,” said Dr. Kristina Deligiannidis, a professor at the Feinstein Institutes for Medical Research in New York. The company said in the announcement that it was the principal investigator on the national multi-center clinical trial that led to Zurzuvae’s approval. “This milestone will hopefully serve as a catalyst for more systemic changes for women suffering from postpartum depression, including much-needed increases in screening, diagnosis and treatment across physician specialties.”

Symptoms of postpartum depression can be debilitating and may include crying, difficulty bonding with your baby, being unable to sleep, or feeling hopeless. Women with severe postpartum depression are unable to carry out normal daily activities and often have recurring thoughts of suicide, self-harm, or harming their baby. These are very serious symptoms that require immediate evaluation and attention.

“We are committed to working with health care providers so that women suffering from postpartum depression do not face this isolating condition alone,” Alisha A. Alaimo, president of Biogen’s North American organization, said in a statement. “We are proud to offer the first oral therapy specifically for women with postpartum depression, and we hope this milestone will advance ongoing efforts by federal and health organizations to improve maternal mental health care.”

Biogen and Sage said Thursday they have launched a patient support program called “Zurzuvae For You,” which includes financial assistance such as a copay assistance program and free medication for those who qualify.

“Innovations will only have an impact if people have access to them, and we will continue to support the goal of broad and equitable access. Our support programs are designed to help women with PPD taking Zurzuvae have as little out-of-pocket costs as possible and be able to “We believe that lack of insurance or financial means should not be a barrier to accessing treatment,” Chris Benecchi, chief commercial officer of Sage Therapeutics, said in a statement Thursday. “

Other oral options for treating postpartum depression are selective serotonin reuptake inhibitors, or SSRIs, which are antidepressant drugs that “take several weeks to work and must be taken daily for at least 6 to 12 months,” Private Psychiatry says Dr. Katrina Furey. A clinical lecturer at Yale University who specializes in women’s mental health and reproductive psychiatry said last November.

Furey said Zurzuvae’s price seemed particularly high compared with those drugs. SSRIs, including generics like Prozac and Zoloft, typically cost less than $20 per month, according to GoodRx.

“It remains to be seen how much insurance companies will cover, or whether they will require women to pay for this new treatment only after they ‘fail’ with cheaper SSRI treatments,” Furey said. “I hope that’s not the case and that the price won’t be a barrier to accessing this treatment.”

However, she points out that the $15,900 price tag is less than half the price of Zulresso, an early postpartum depression drug produced by Sage. The drug, which costs about $35,000, is infused intravenously in a hospital for 60 hours.

#drug #postpartum #depression #U.S #drugmaker
Image Source : www.wesh.com

Leave a Comment